Stereotactic body radiation therapy in pancreatic cancer: the new frontier EXPERT REVIEW OF ANTICANCER THERAPY Moningi, S., Marciscano, A. E., Rosati, L. M., Ng, S. K., Forbang, R. T., Jackson, J., Chang, D. T., Koong, A. C., Herman, J. M. 2014; 14 (12): 1461-1475


Pancreatic cancer (PCA) remains a disease with a poor prognosis. The majority of PCA patients are unable to undergo surgical resection, which is the only potentially curative option at this time. A combination of chemotherapy and chemoradiation (CRT) are standard options for patients with locally advanced, unresectable disease, however, local control and patient outcomes remains poor. Stereotactic body radiation therapy (SBRT) is an emerging treatment option for PCA. SBRT delivers potentially ablative doses to the pancreatic tumor plus a small margin over a short period of time. Early studies with single-fraction SBRT demonstrated excellent tumor control with high rates of toxicity. The implementation of SBRT (3-5 doses) has demonstrated promising outcomes with favorable tumor control and toxicity rates. Herein we discuss the evolving role of SBRT in PCA treatment.

View details for DOI 10.1586/14737140.2014.952286

View details for Web of Science ID 000346639100008

View details for PubMedID 25183386